Sentiment Still Eluding 3SBio Inc. (HKG:1530)
3SBio Unit Gets Commercialization Rights for Duality Biologics' Cancer Drug in China, Hong Kong, Macau
Express News | 3Sbio - Cooperation Between 3Sbio Inc. and Duality Biologics in Respect of Her2 ADC Drug
Both Individual Investors Who Control a Good Portion of 3SBio Inc. (HKG:1530) Along With Institutions Must Be Dismayed After Last Week's 3.8% Decrease
3SBio Cancels All Treasury Shares
3SBio's Unit Gets Exclusive Commercialization Rights for Clifutinib Besylate in Mainland China
3SBio Partners With Sunshine Lake Pharma for Drug Rights
Express News | 3Sbio - Cooperation Between Shenyang Sunshine and Sunshine Lake Pharma in Respect of Clifutinib Besylate
3SBio (HKG:1530) Has A Pretty Healthy Balance Sheet
3SBio's Mandi Shines in 2024 Double 11 Sales
3SBio CFO Boosts Shareholding, Confident in Future
Express News | 3Sbio - Since 1 Jan to 14 Nov, CFO Increased Shareholding in Co by Aggregate of 3.0 Mln Ordinary Shares at HKD5.99 per Share
The Five-year Underlying Earnings Growth at 3SBio (HKG:1530) Is Promising, but the Shareholders Are Still in the Red Over That Time
3SBio Arm to Obtain Commercialization Rights for RMX Biopharma's Paclitaxel Oral Solution
3SBio Secures Exclusive Rights for Cancer Drug
Express News | 3Sbio - Cooperation Agreement With Shanghai Haihe Biopharma Research and Development, Others
Express News | 3Sbio - Unit Entered Into Paclitaxel Oral Solution Exclusive Commercialization Cooperation Agreement
Trending Industry Today: FOSUN PHARMA Leads Losses In Aesthetic Medicine Stocks
Trending Industry Today: SIHUAN PHARM Leads Gains In Aesthetic Medicine Stocks
Express News | 3Sbio H1 Basic EPS RMB 0.45